Growth Metrics

Acadia Pharmaceuticals (ACAD) Receivables - Net: 2009-2025

Historic Receivables - Net for Acadia Pharmaceuticals (ACAD) over the last 11 years, with Sep 2025 value amounting to $115.8 million.

  • Acadia Pharmaceuticals' Receivables - Net rose 17.96% to $115.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.8 million, marking a year-over-year increase of 17.96%. This contributed to the annual value of $98.7 million for FY2024, which is 0.48% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Receivables - Net of $115.8 million as of Q3 2025, which was up 7.76% from $107.5 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Receivables - Net high stood at $115.8 million for Q3 2025, and its period low was $51.4 million during Q2 2021.
  • For the 3-year period, Acadia Pharmaceuticals' Receivables - Net averaged around $96.7 million, with its median value being $98.3 million (2023).
  • In the last 5 years, Acadia Pharmaceuticals' Receivables - Net dropped by 8.18% in 2022 and then surged by 66.51% in 2023.
  • Acadia Pharmaceuticals' Receivables - Net (Quarterly) stood at $64.4 million in 2021, then fell by 3.37% to $62.2 million in 2022, then skyrocketed by 58.00% to $98.3 million in 2023, then rose by 0.48% to $98.7 million in 2024, then rose by 17.96% to $115.8 million in 2025.
  • Its Receivables - Net stands at $115.8 million for Q3 2025, versus $107.5 million for Q2 2025 and $105.7 million for Q1 2025.